Product Description
PharmAust is developing Monepantel as a treatment for pet dog naive B cell lymphoma. (Sourced from: https://www.pharmaust.com/petdogtrial/)
Mechanisms of Action: nAChR Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | Poland
Approved Indications: None
Known Adverse Events: None
Company: PharmAust
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Amyotrophic Lateral Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06177431 |
MON-2023-001 | P1 |
Completed |
Amyotrophic Lateral Sclerosis |
2025-05-30 |
50% |
2025-06-05 |
Primary Endpoints|Treatments|Trial Status |
NCT04894240 |
MON-2021-001 | P1 |
Completed |
Amyotrophic Lateral Sclerosis |
2023-11-29 |
50% |
2023-12-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |